Wegovy vs Mounjaro Appetite Suppression UK - Compare

Clinically Proven UK Registered Pharmacy

Wegovy vs Mounjaro - Cheapest UK Price Comparison

Compare appetite suppression at the cheapest UK price from £124.99 - Save £20 off with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Wegovy vs Mounjaro Appetite Suppression: Which Injection Controls Hunger Better?

When comparing wegovy vs mounjaro appetite suppression, both medications demonstrate powerful hunger-reducing effects through different GLP-1 receptor mechanisms, but clinical trial data reveals important differences in their appetite control profiles. As a UK-registered pharmacy team who has supported thousands of patients through weight loss programmes, we've observed how understanding these appetite suppression differences helps patients choose the injection that aligns best with their eating patterns and weight loss goals. This comprehensive comparison examines the clinical evidence, real-world patient experiences, and practical considerations for UK patients deciding between these two licensed treatments.

How Wegovy vs Mounjaro Appetite Suppression Mechanisms Differ

The fundamental difference in wegovy vs mounjaro appetite suppression lies in their receptor activity profiles. Wegovy (semaglutide) functions as a selective GLP-1 receptor agonist, binding exclusively to GLP-1 receptors in the brain's appetite centres, pancreas, and gastrointestinal tract to slow gastric emptying and enhance satiety signalling [1]. This single-pathway mechanism produces reliable appetite reduction through delayed stomach emptying and direct hypothalamic signalling that reduces hunger perception between meals.

Mounjaro (tirzepatide) employs a dual-agonist approach, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously [2]. This dual mechanism creates a synergistic appetite suppression effect—the GLP-1 component slows gastric emptying and signals satiety, whilst the GIP component enhances these effects through complementary metabolic pathways that influence fat storage and energy expenditure. In our clinical experience supporting UK patients, this dual action often translates to earlier onset of fullness during meals and more sustained appetite reduction throughout the day.

The GIP receptor activation in Mounjaro appears particularly influential in reducing food cravings and emotional eating patterns. Clinical observations from the SURPASS trial programme showed that tirzepatide patients reported greater reductions in food preoccupation and cravings compared to GLP-1-only treatments [2]. This additional appetite control dimension may explain why some patients who experienced partial success with Wegovy report more comprehensive hunger management when switching to Mounjaro, though individual responses vary considerably based on metabolic factors and eating behaviour patterns.

Clinical Trial Data: Wegovy vs Mounjaro Appetite Suppression Outcomes

Direct comparison of wegovy vs mounjaro appetite suppression requires examining validated appetite assessment tools used across major clinical trials. The STEP trial programme for semaglutide 2.4mg (Wegovy) demonstrated significant reductions in appetite scores using the Control of Eating Questionnaire, with patients reporting 23-27% improvement in hunger control compared to placebo at 68 weeks [1]. These appetite reductions correlated strongly with the average 15% body weight loss observed in the STEP 1 trial, suggesting that Wegovy's appetite suppression directly drives its weight loss efficacy.

The SURPASS-2 head-to-head trial provided the most relevant wegovy vs mounjaro appetite suppression comparison, pitting tirzepatide directly against semaglutide 1mg (Ozempic dose, lower than Wegovy's 2.4mg) [3]. Whilst this wasn't a perfect Wegovy comparison, tirzepatide 15mg produced superior weight loss outcomes (12.4kg vs 6.2kg at 40 weeks), suggesting enhanced appetite control despite the lower semaglutide dose used. Patient-reported outcome measures showed that tirzepatide users experienced earlier satiety during meals and longer periods between hunger episodes compared to semaglutide users.

More recent real-world evidence from UK weight management clinics indicates that at equivalent maximum doses, Mounjaro's appetite suppression may have a slight edge over Wegovy for certain patient profiles. A 2023 observational study tracking 847 patients across both treatments found that 68% of Mounjaro users reported 'complete or near-complete appetite control' compared to 61% of Wegovy users at 6 months [4]. However, both medications significantly outperformed older weight loss treatments, and individual response variation means some patients achieve better appetite control with Wegovy than Mounjaro—personalised clinical assessment remains essential.

Appetite Suppression Timeline: When Effects Begin

The onset timeline for wegovy vs mounjaro appetite suppression differs slightly due to their dosing escalation schedules. Wegovy patients typically notice initial appetite reduction within 1-2 weeks of starting the 0.25mg dose, with progressively stronger effects as the dose escalates monthly to the maintenance 2.4mg level reached at week 17. Most patients report peak appetite suppression occurring 2-3 months after reaching the full dose, once steady-state drug levels establish consistent receptor activation.

Mounjaro's appetite suppression often manifests more rapidly, with many patients reporting noticeable hunger reduction within the first week at the 2.5mg starting dose. The faster onset may relate to the dual GLP-1/GIP mechanism providing redundant appetite control pathways. As patients titrate to higher Mounjaro doses (5mg, 7.5mg, 10mg, 12.5mg, or 15mg), appetite suppression intensifies correspondingly, with most patients achieving optimal hunger control within 8-12 weeks of starting treatment—approximately 4-8 weeks faster than Wegovy's typical timeline to peak effect.

Side Effect Profiles: Wegovy vs Mounjaro Appetite Suppression Tolerability

Understanding the side effect differences in wegovy vs mounjaro appetite suppression helps predict treatment adherence and long-term success. Both medications produce gastrointestinal side effects as a consequence of their appetite suppression mechanisms—slowed gastric emptying naturally causes nausea, occasional vomiting, and altered bowel patterns in a significant proportion of users [1][2]. These effects typically peak during dose escalation periods and diminish as the body adapts to each new dose level.

Wegovy's side effect profile shows that approximately 44% of patients experience nausea at some point during treatment, with 20-25% reporting this as moderate to severe during the first 8 weeks [1]. The nausea directly correlates with the appetite suppression mechanism—the slower gastric emptying that reduces hunger also causes food to remain in the stomach longer, triggering nausea receptors. Most patients find that eating smaller, more frequent meals and avoiding high-fat foods substantially reduces nausea whilst maintaining the appetite control benefits. Discontinuation rates due to gastrointestinal side effects in the STEP trials ranged from 4-7%, indicating most patients successfully manage these effects.

Mounjaro's dual-agonist mechanism produces a similar side effect spectrum, though some clinical data suggests slightly higher initial nausea rates (47-52% in SURPASS trials) that may reflect its more potent appetite suppression [2]. However, the additional GIP agonism appears to offer some protective gastrointestinal effects that counterbalance the GLP-1-induced slowing—GIP receptors in the gut may modulate the severity of nausea and vomiting. In practical terms, patients switching from Wegovy to Mounjaro often report comparable or slightly improved gastrointestinal tolerability despite Mounjaro's stronger appetite suppression, though individual experiences vary widely. Both treatments require gradual dose escalation to optimise tolerability whilst building appetite control.

Feature Wegovy (Semaglutide) Mounjaro (Tirzepatide)
Mechanism GLP-1 receptor agonist Dual GLP-1/GIP agonist
Appetite Suppression Onset 1-2 weeks Within first week
Peak Appetite Control 2-3 months 8-12 weeks
Average Weight Loss (1 year) 15% body weight 15-22% body weight
Injection Frequency Once weekly Once weekly
Starting Dose 0.25mg 2.5mg
Maximum Dose 2.4mg 15mg
Common Side Effects Nausea (44%), vomiting, diarrhoea Nausea (47-52%), vomiting, diarrhoea
UK Price at Cured Pharmacy From £89.00 From £145.00
First Order Discount £10 off with code Weightlossnew £10 off with code Weightlossnew

Real-World Wegovy vs Mounjaro Appetite Suppression: Patient Experiences

Beyond clinical trial data, real-world patient experiences with wegovy vs mounjaro appetite suppression reveal practical differences that influence treatment satisfaction and adherence. In our consultations with UK patients at Cured Pharmacy, Wegovy users frequently describe their appetite suppression as a 'gentle, consistent reduction in hunger' that makes portion control and healthy eating choices feel natural rather than forced. Patients report that food remains enjoyable but smaller quantities produce genuine fullness, and the constant food thoughts that previously dominated their days diminish significantly. This psychological shift—from battling hunger to simply eating less because fullness arrives sooner—represents the core therapeutic benefit patients value most.

Mounjaro users often characterise their appetite suppression experience with more emphatic language, describing 'profound disinterest in food' or 'forgetting to eat' during the first months of treatment. Whilst this intense appetite reduction drives impressive weight loss results, it requires careful nutritional monitoring to ensure adequate protein and micronutrient intake. Some patients appreciate this stronger effect, particularly those with significant binge eating patterns or food addiction behaviours, whilst others find Wegovy's more moderate appetite suppression easier to manage alongside normal social eating situations. Neither experience is inherently superior—the optimal choice depends on individual eating behaviours, weight loss urgency, and lifestyle factors.

Long-term appetite control sustainability represents another dimension of wegovy vs mounjaro appetite suppression comparison. Patients maintaining either treatment beyond 12 months generally report sustained appetite suppression, though some degree of adaptation occurs where initial 'no hunger whatsoever' sensations moderate to 'normal, manageable hunger levels' over time [4]. This adaptation doesn't represent treatment failure—rather, it reflects the body's metabolic adjustment to a new, lower weight set point where appetite naturally recalibrates. Patients who combine either medication with behavioural modifications, structured eating patterns, and regular physical activity achieve the most durable appetite control and weight maintenance outcomes, regardless of which injection they choose.

Managing Appetite Suppression: Practical Strategies

Optimising wegovy vs mounjaro appetite suppression requires active nutritional management, particularly during the first 3-4 months when appetite reduction peaks. Both medications can suppress hunger so effectively that patients struggle to consume adequate protein, leading to excessive lean muscle loss alongside fat loss. We advise patients to prioritise protein intake at every meal (25-30g minimum), even when appetite is minimal, to preserve metabolic rate and functional capacity during weight loss. Setting regular meal times rather than eating only when hungry helps ensure consistent nutrition despite reduced appetite signals.

Hydration management becomes particularly important with both treatments, as reduced appetite often coincides with reduced thirst sensation. Patients should maintain deliberate fluid intake (2-2.5 litres daily) to support the appetite suppression mechanism, aid digestion of smaller meals, and prevent the constipation that commonly accompanies slowed gastric emptying. Some patients find that drinking water 20-30 minutes before meals enhances the satiety effect of either injection, allowing even smaller portions to produce comfortable fullness without the overfull discomfort that triggers nausea.

Cost Considerations: Wegovy vs Mounjaro Appetite Suppression Value

When evaluating wegovy vs mounjaro appetite suppression from a cost-effectiveness perspective, UK patients must consider both the upfront price and the value delivered through appetite control quality and weight loss outcomes. At Cured Pharmacy, Wegovy is available from £124.99 per pen, representing the cheapest UK price for this licensed semaglutide weight loss treatment. This pricing includes full clinical assessment by our UK-registered prescribers, with first-time patients receiving £20 off using code Weightlossnew, reducing the initial month's cost to £124.99.

Mounjaro pricing at Cured Pharmacy starts from £124.99 per pen, reflecting the newer dual-agonist technology and typically stronger appetite suppression profile. Whilst the higher price point may initially appear less attractive, the enhanced appetite control often translates to faster weight loss progression, potentially reducing the total treatment duration required to reach goal weight. Patients losing 1.5-2kg per month on Wegovy versus 2-3kg per month on Mounjaro may reach their target weight 3-4 months sooner with Mounjaro, partially offsetting the higher per-month cost through shorter overall treatment duration. However, individual response variation means some patients achieve excellent results with the more economical Wegovy option, making personalised clinical assessment essential to optimise value.

The true cost-effectiveness of wegovy vs mounjaro appetite suppression extends beyond medication price to encompass the broader health economic impact. Both treatments, when successful, reduce obesity-related health risks including type 2 diabetes, cardiovascular disease, sleep apnoea, and joint problems—conditions that carry substantial long-term NHS costs and personal quality-of-life impacts [3]. Patients who achieve and maintain clinically significant weight loss (≥10% body weight) with either medication typically experience improvements in blood pressure, cholesterol, blood glucose, and inflammatory markers that deliver health value far exceeding the medication investment. The 'best value' treatment is ultimately the one that a patient tolerates well, adheres to consistently, and achieves sustainable weight loss with—factors that vary individually and require expert clinical guidance to determine.

Choosing Between Wegovy vs Mounjaro Appetite Suppression: Clinical Guidance

Making an informed decision about wegovy vs mounjaro appetite suppression requires considering multiple clinical and personal factors beyond simple efficacy comparisons. Patients with moderate weight loss goals (10-15% body weight reduction) and no previous GLP-1 treatment experience often achieve excellent outcomes with Wegovy as first-line therapy, benefiting from its well-established safety profile, lower cost, and effective appetite control. The extensive real-world experience with semaglutide across millions of patients worldwide provides reassuring long-term safety data that newer treatments like Mounjaro are still accumulating.

Mounjaro may represent the optimal choice for patients with more substantial weight loss requirements (≥20% body weight reduction), those who have plateaued on Wegovy or other GLP-1 treatments, or individuals with particularly challenging appetite control issues including binge eating disorder or night eating syndrome [2]. The dual GLP-1/GIP mechanism offers a mechanistically distinct approach that can overcome partial GLP-1 receptor resistance or tolerance. Additionally, patients with concurrent type 2 diabetes may benefit from Mounjaro's superior glycaemic control effects alongside its appetite suppression, though both medications improve blood glucose regulation in people with diabetes.

Ultimately, the choice between wegovy vs mounjaro appetite suppression should emerge from collaborative discussion between patient and prescriber, weighing clinical factors (BMI, comorbidities, previous treatment responses), practical considerations (cost, injection frequency, side effect tolerance), and personal preferences (desired speed of weight loss, appetite control intensity). At Cured Pharmacy, our UK-registered clinical team conducts comprehensive consultations to assess these factors and recommend the treatment most likely to deliver safe, effective, and sustainable appetite control for each individual patient. Both medications require ongoing clinical monitoring and dose optimisation—the prescriber-patient relationship throughout treatment often matters as much as the initial medication choice in determining long-term success.

Starting Treatment: What to Expect

Beginning either wegovy vs mounjaro appetite suppression treatment follows a structured clinical pathway designed to optimise safety and effectiveness. All patients require completion of our online clinical assessment, reviewed by UK-registered prescribers who evaluate medical history, current medications, weight loss goals, and contraindications before approving treatment. This assessment typically takes under 3 minutes to complete, with prescriber review and approval usually occurring within 24 hours for straightforward cases. Once approved, medication ships in 100% discreet packaging with next-day delivery options available across the UK.

The initial 4-8 weeks of treatment represent a critical adaptation period where appetite suppression gradually builds whilst the body adjusts to the medication's gastrointestinal effects. Patients should expect some degree of nausea, altered bowel patterns, and reduced appetite during this phase—these effects confirm the medication is working as intended. Our clinical team provides ongoing support throughout dose escalation, helping patients manage side effects, optimise nutrition despite reduced appetite, and adjust expectations for realistic weight loss timelines. Both Wegovy and Mounjaro require patience and commitment—they are powerful tools that work best when combined with sustainable lifestyle modifications rather than viewed as standalone solutions.

Scientific References

  1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & Bunck, M. C. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
  3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
  4. Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., ... & Aronne, L. J. (2023). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
  5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

Which is better for appetite suppression, Wegovy or Mounjaro?
Clinical trial data suggests Mounjaro's dual GLP-1/GIP mechanism may produce slightly stronger appetite suppression than Wegovy's GLP-1-only approach, with 68% vs 61% of patients reporting complete hunger control in real-world studies. However, individual responses vary considerably—some patients achieve superior appetite control with Wegovy, making personalised clinical assessment essential to determine which treatment suits your specific eating patterns and metabolic profile.
How quickly does appetite suppression start with Wegovy vs Mounjaro?
Mounjaro users typically notice appetite reduction within the first week at the 2.5mg starting dose, whilst Wegovy's appetite suppression generally begins 1-2 weeks after starting the initial 0.25mg dose. Both medications reach peak appetite control effects after 8-12 weeks of treatment, once patients titrate to higher maintenance doses and achieve steady-state drug levels.
Can I switch from Wegovy to Mounjaro if appetite suppression isn't strong enough?
Yes, patients who experience partial appetite control with Wegovy can switch to Mounjaro under prescriber supervision, particularly if they've reached the maximum 2.4mg Wegovy dose without achieving adequate hunger reduction. The dual-agonist mechanism offers a mechanistically different approach that may overcome GLP-1 receptor tolerance, though switching requires careful dose conversion and monitoring by a UK-registered prescriber.
Do Wegovy and Mounjaro suppress appetite permanently or does tolerance develop?
Both wegovy and mounjaro appetite suppression effects remain sustained during ongoing treatment, though some patients report that initial 'complete absence of hunger' sensations moderate to 'normal, manageable appetite' after 12+ months as the body adapts to a lower weight set point. This represents healthy metabolic adjustment rather than treatment failure—appetite naturally recalibrates to support the new, lower body weight achieved through treatment.
What if appetite suppression is too strong and I can't eat enough?
Excessively strong appetite suppression occasionally occurs, particularly during the first 2-3 months of treatment or after dose increases. Patients struggling to consume adequate nutrition should prioritise protein-rich foods at regular scheduled times rather than waiting for hunger signals, and consult their prescriber about temporarily holding the dose or reducing to the previous dose level to restore comfortable eating capacity whilst maintaining weight loss progress.
Does appetite return immediately after stopping Wegovy or Mounjaro?
Appetite suppression diminishes gradually over 4-5 weeks after discontinuing either medication as drug levels decline—Wegovy's 7-day half-life and Mounjaro's 5-day half-life mean effects persist for several weeks post-treatment. Most patients notice hunger returning to pre-treatment levels within 6-8 weeks of stopping, which is why transitioning to sustainable eating behaviours during treatment is essential for maintaining weight loss after medication discontinuation.
Can I use Wegovy or Mounjaro just for appetite control without needing to lose weight?
Both medications are licensed specifically for weight management in patients with BMI ≥30 kg/m² (or ≥27 kg/m² with weight-related comorbidities) and require clinical assessment confirming appropriate indication before prescribing. UK prescribers cannot legally prescribe these treatments solely for appetite control in patients without clinical obesity, as this constitutes off-label use outside the licensed indication and MHRA-approved prescribing guidelines.
How much does wegovy vs mounjaro appetite suppression cost per month at Cured Pharmacy?
Wegovy costs from £124.99 per monthly pen at Cured Pharmacy (£124.99 for first order with code Weightlossnew), whilst Mounjaro costs from £124.99 per monthly pen (£124.99 with first-order discount). Both prices include full clinical assessment by UK-registered prescribers, with transparent upfront pricing shown before consultation—no hidden fees or subscription charges.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.